Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00090363
Status:
COMPLETED
Last Update Posted:
2013-01-08
First Post:
2004-08-25
Brief Title:
ZD4054 Zibotentan in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen PSA
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Randomized Double-blind Parallel-group Placebo-controlled Multi-centre Study to Assess ZD4054 Zibotentan in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen PSA
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being carried out to see if ZD4054 Zibotentan is effective in treating prostate cancer and spread of cancer to the bone and if so how it compares with placebo sugar pill The study will also provide further information on the safety of ZD4054 Zibotentan
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Trial 6 | None | None | None |
| ZD4054 | None | None | None |